导师姓名： 李宗海 专业代码： 100214
性别： 男 专业名称： 肿瘤学
培养单位： 附属仁济医院 三级学科/
专业领域：
导师类型： 博士生导师 专业学位导师：
联系方式： Email: zonghaili@shsmu.edu.cnTel: Add: 上海市斜土路2200弄25号
邮编： 200032 邮箱地址： zonghaili@shsmu.edu.cn

研究方向 (点击浏览详细信息)
肿瘤靶向生物治疗

社会任职
国际创新药物研发联盟（IAIDR）执行理事
美国基因治疗协会ASGCT会员
中国转化医学联盟 常务理事
中国医药生物技术协会基因治疗分会首届委员
中国临床肿瘤学会转化医学专家委员会?常委
上海市医药质量协会细胞免疫质量管理与研究专业委员会 主任委员
国家自然科学基金委和上海市科委项目评审专家
美国癌症协会（AACR）会员

科研项目 项目编号项目名称课题来源起止年月批准经费承担职责
** 嵌合细胞因子受体chIL4-21R对CAR-T细胞的增效作用及其机制研究 国家自然科学基金 2019-01~2022-12 58万元 课题负责人
** EGFR调控SCD1蛋白稳定性的机制及其对肿瘤发生发展的作用研究 国家自然科学基金 2017-01~2020-12 57万元 课题负责人
2017ZX CARgpc3 T细胞的肝癌联合免疫治疗研究 十三五国家传染病重大专项 2017-01~2020-12 169.83万元 课题负责人
16XD** CAR-GPC3 T细胞在肝细胞癌中的早期临床研究 上海市科学技术委员会(上海市优秀学科带头人) 2016-05~2019-04 40万元 课题负责人
** 表皮生长因子受体异构体EGFRvA对HNRNPF的调控和机制研究 国家自然科学基金 2015-01~2018-12 80万元 课题负责人
XBR** 靶向EGFR与CD3的双特异抗体的研制及用于胶质瘤的实验治疗研究 上海市卫生和计划生育委员会"新****" 2014-01~2016-12 45万元 课题负责人
2012ZX09103-301-005 抗肿瘤候选药物表皮生长因子受体变异体单克隆抗体CH12的研究 十二五国家科技“重大新药创制专项” 2012-01~2015-12 145.19万元 子课题负责人
2012ZX**-006 肝癌靶向性脂质体药物 十二五国家科技“艾滋病和病毒性肝炎等重大传染病防治专项” 2012-01~2015-12 175.44万元 子课题负责人
** 表皮生长因子受体新异构体EGFRvA促进肿瘤转移的分子机制 国家自然科学基金 2011-01~2013-12 32万元 课题负责人
抗表皮生长因子受体III型变异体单克隆抗体介导的靶向药物 上海市科学技术委员会(生物医药重点科技攻关) 2010-07~2013-09 25万元 课题负责人
07QA14046 EGFRvIII单克隆抗体的活性鉴定及其用于脑胶质瘤的靶向治疗研究 上海市科学技术委员会 2007-09~2009-09 13万元 课题负责人
** 表皮生长因子受体的肽配体与阳离子多肽及核定位信号的基因工程融合表达及其基因导入研究 国家自然科学基金 2007-01~2009-12 26万元 课题负责人
** EGFR单链抗体的筛选及其在肺癌诊断中的应用 上海市科学技术委员会 2005-12~2008-09 15万元 课题负责人

学术论文 作者论文标题期刊名出版年卷期页码
Donghua Shi, Yaoping Shi, Ahmed O Kaseb, Xingxing Qi, Yuan Zhang, Jiachang Chi, Qing Lu, Huiping Gao, Hua Jiang, Huamao Wang, Daijing Yuan, Hong Ma, Hongyang Wang, Zonghai Li* and Bo Zhai* （通讯作者） Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials Clin Cancer Res. 2020 26(15):3979-3989
Ying Liu,Shengmeng Di, Bizhi Shi,Honghong Zhang,Yi Wang,Xiuqi Wu,Hong Luo, Huamao Wang,Zonghai Li （通讯作者）,and Hua Jiang Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma J Immunol. 2019 203(1):198-207
Xiuqi Wu, Hong Luo, Bizhi Shi,Shengmeng Di,Ruixin Sun,Jingwen Su,Ying Liu, Hua Li,Hua Jiang,and Zonghai Li （通讯作者） Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma Molecular Therapy 2019 27(8):1483-1494.
Shengmeng Di, Min Zhou, Zeyan Pan, Ruixin Sun, Muhua Chen, hua jiang, Bizhi Shi, Hong Luo, Zonghai Li （通讯作者） Combined adjuvant of poly I:C improves antitumor effects of CAR-T cells Front. Oncol. 2019 9：241
Hong Luo, Xiuqi Wu, Ruixin Sun, Jingwen Su, Yi Wang, Yiwei Dong, Bizhi Shi, Yansha Sun, Hua Jiang, Zonghai Li* （通讯作者） Target-dependent expression of IL12 by synNotch receptor-engineered NK92 cells increases the antitumor activities of CAR-T cells Frontiers in Oncology 2019 9: 1448
Yi Wang, Hua Jiang, Hong Luo, Yansha Sun, Bizhi Shi , Ruixin Sun and Zonghai Li* An IL-4/21?Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment Frontiers in Immunology 2019 10:1691
Hua Jiang, Zhimin Shi, Peng Wang, Cong Wang, Linlin Yang, Guoxiu Du, Honghong Zhang, Bizhi Shi, Jie Jia, Qixiang Li, Huamao Wang, Zonghai Li （通讯作者） Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer J Natl Cancer Inst 2019 111(4):409-418
Zeyan Pan,Shengmeng Di,Bizhi Shi,Hua Jiang, Zhimin Shi, Ying Liu, Yi WangHong, LuoMin Yu, Xiuqi Wu, Zonghai Li （通讯作者） Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein Cancer Immunol Immunother 2018 67:1621-1634
Min Yu,Hong Luo,Mingliang Fan,Xiuqi Wu,Bizhi Shi,Shengmeng Di,Ying Liu, Zeyan Pan,Hua Jiang,and Zonghai Li （通讯作者） Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma Molecular Therapy 2018 26(2):366-378
Hua Jiang, Huiping Gao, Juan Kong, Bo Song, Peng Wang, Bizhi Shi, Huamao Wang and Zonghai Li Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bi-targeted Chimeric Antigen Receptor T Cell Cancer Immunol Res. 2018 6(11):1314-1326
Xingliang Guo, Hua Jiang, Bizhi Shi, Min Zhou, Honghong Zhang, Zhimin Shi, Guoxiu Du, Hong Luo, Xiuqi Wu, Yi Wang, Ruixin Sun and Zonghai Li Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells against Hepatocellular Carcinoma Frontiers Pharmacology 2018 9:1118
Xiuqi Wu, Bizhi Shi, Jiqin Zhang, Zhimin Shi, Shengmeng Di, Minliang Fan, Huiping Gao, Hai Wang, Jianren Gu, Hua Jiang, Zonghai Li （通讯作者） A fusion receptor as a safety switch, detection and purification biomarker for adoptive transferred T cells Molecular Therapy 2017 25(10):2270-2279
Chen Chong,Liu Kong,Xu yupeng,Zhang Pengwei, Suo Yan, Lu Yi, Zhang Wenyuan, Su Li, Gu Qing,Wang Huamao, Gu Jianren, Li Zonghai （通讯作者）, Xu Xun Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution Biomaterials 2017 112：218-233
Jiang Hua, Song Bo, Wang Peng, Shi Bizhi, Li Qixiang, Fan Mingliang, Di Shengmeng, Yang Jie, Li Zonghai （通讯作者） Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells Protein & cell. 2017 8(12):926-931
Cheng Chen, Kesang Li, Hua Jiang, Fei Song, Huiping Gao, Xiaorong Pan, Bizhi Shi, Yanyu Bi, Huamao Wang, Hongyang Wang, Zonghai Li （通讯作者） Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma Cancer Immunol Immunother. 2017 66(4):475-489
Yanyu Bi#, Hua Jiang#, Peng Wang, Bo Song, Huamao Wang, Xianming Kong and Zonghai Li Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager Oncotarget 2017 8(32): 52866-52876
Jiqin Zhang Fei Song, Xiaojing Zhao, Hua Jiang, Xiuqi Wu, Biao Wang, Min Zhou, Mi Tian, Bizhi Shi, Huamao Wang, Yuanhui Jia, Hai Wang, Xiaorong Pan and Zonghai Li EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer Molecular Cancer 2017 16:127
BiaoWang, Jiqin Zhang, Fei Song, Mi Tian, Bizhi Shi, Hua Jiang, Wen Xu, HaiWang, Min Zhou, Xiaorong Pan, Jianren Gu, Shengli Yang , Liyan Jiang, Zonghai Li （通讯作者） EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1 Cancer Letters 2016 381: 331–340
Wen Xu, Yanyu Bi, Juan Kong, Jiqin Zhang, Biao Wang, Kesang Li, Mi Tian,Xiaorong Pan, Bizhi Shi, Jianren Gu, Hua Jiang, Xianming Kong, Zonghai Li （通讯作者） Combination of CH12 with Rapamycin Synergistically Inhibits the Growth of EGFRvIII+PTEN- Glioblastoma in Vivo Oncotarget 2016 7（17）:24752-24765
Fei Song, Min Zhou, Biao Wang, Bizhi Shi, Hua Jiang, Jiqin Zhang and Zonghai Li Weak?binding?to?E3?ubiquitin?ligase?c-Cbl?increases?EGFRvA?protein?stability. FEBS Lett. 2016 590(9):1345-53.
Xiaofei Liang, Bizhi Shi, Kai Wang , Mingliang Fan, Dejin Jiao, Junping Ao,Na Song, Chun Wang, Jianren Gu, Zonghai Li （通讯作者） Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery Biomaterials 2016 82: 194-207
Wen Xu, Yanyu Bi, Jiqin Zhang, Juan Kong, Hua Jiang, Mi Tian, Kesang Li, Biao Wang, Cheng Chen, Fei Song, Xiaorong Pan, Bizhi Shi, Xianming Kong, Jianren Gu, Xiumei Cai and Zonghai Li Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12. Oncotarget 2015 6(36):38840-53
Pengfei Zhang, Bizhi Shi ,Huiping Gao,Hua Jiang, Juan Kong,Jin Yan, Xiaorong Pan, Kesang Li, Pengwei Zhang, Ming Yao, Shengli Yang, Jianren Gu ,Hongyang Wang, Zonghai Li （通讯作者） An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression Cancer Immunol Immunother 2014 63(2):121-32
Ma K, Pan X, Fan P, He Y, Gu J, Wang W, Zhang T, Li Z （通讯作者）, Luo X. Loss of miR-638 in vitro promotes cell invasion and a mesenchymal-like transition by influencing SOX2 expression in colorectal carcinoma cells. Mol Cancer 2014 13:118
Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, Li Z. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 2014 20(24):6418-28
Jiang H, Dong Q, Luo X, Shi B, Wang H, Gao H, Kong J, Zhang J, Li Z. （通讯作者） The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Cancer Lett 2014 342(1):113-20
Liang X, Li X, Chang J, Duan Y, Li Z. （通讯作者） Properties and evaluation of quaternized chitosan/lipid cation polymeric liposomes for cancer-targeted gene delivery. Langmuir 2013 29(27):8683-93.
Luo X, Xie H, Long X, Zhou M, Xu Z, Shi B, Jiang H, Li Z （通讯作者） EGFRvIII Mediates Hepatocellular Carcinoma Cell Invasion by Promoting S100 Calcium Binding Protein A11 Expression. PLoS One 2013 8(12):e83332
Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H, Pan X, Gao H, Sun H, Li Z. （通讯作者） Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis 2013 5:e991
Min Zhou, Hai Wang, Keke Zhou, Xiaoying Luo, Xiaorong Pan, Bizhi Shi, Hua Jiang, Jiqin Zhang, Kesang Li, Hua-Mao Wang, Huiping Gao, Shun Lu, Ming Yao1, Ying Mao, Hong-Yang Wang Shengli Yang, Jianren Gu1, Chuanyuan Li, and Zonghai Li A Novel EGFR Isoform Confers Increased Invasiveness to Cancer Cells Cancer Res 2013 73(23):7056-67.
Zhang P, Zhang P, Zhou M, Jiang H, Zhang H, Shi B, Pan X, Gao H, Sun H, Li Z. （通讯作者） Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer. Carcinogenesis 2013 34(11):2639-46
Yaqiong Yang, Hua Jiang, Huiping Gao, Juan Kong, Pengwei Zhang, Suwen Hu, Bizhi Shi, Pengfei Zhang, Ming Yao, Zonghai Li. （通讯作者） The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III. Neoplasia 2012 14(6):509-18
Wang JL, Tang GP, Shen J, Hu QL, Xu FJ, Wang QQ, Li ZH （通讯作者）, Yang WT. A gene nanocomplex conjugated with monoclonal antibodies for targeted therapy of hepatocellular carcinoma. Biomaterials 2012 33(18):4597-607
Liu M, Li ZH （共同第一作者）, Xu FJ, Lai LH, Wang QQ, Tang GP, Yang WT An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy Biomaterials 2012 33(7):2240-50
Hai Wang, Bizhi Shi, Qingli Zhang, Hua Jiang, Suwen Hu, Juan Kong, Ming Yao, Shengli Yang, Zonghai Li （通讯作者） An oligopeptide ligand-mediated Growth and Metastasis Suppression of Glioma Xenografts Expressing Exon 4-deletion Variant of Epidermal Growth Factor Receptor by Monoclonal Antibody CH12–Mediated Receptor Degradation. FASEB J. 2012 26(1): 73-80
Yicheng Wu,Maoquan Chu,Bizhi Shi,Zonghai Li （通讯作者） A Novel Magneto-fluorescent Nano-bioprobe for Cancer Cell Targeting, Imaging and Collection Appl Biochem Biotechnol 2011 163(7):813-25
Min Zhou, Bizhi Shi, Peng Wang, Jianren Gu, Zonghai Li （通讯作者） Large-scale production of functional recombinant CAR in a baculovirus-insect cell system Acta Virol 2011 55(2):93-9
Jiang H, Wang H, Tan Z, Hu S, Wang H, Shi B, Yang L, Li P, Gu J, Wang H, Li Z （通讯作者） Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III J Biol Chem 2011 286(7):5913-20
Hai Wang*, Min Zhou*, Bizhi Shi, Qingli Zhang, Hua Jiang, Yinghao Sun, Jianhua Liu, Keke Zhou, Ming Yao, Jianren Gu, Shengli Yang,Ying Mao, Zonghai Li （通讯作者） Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity Neoplasia 2011 13（5）：461-71
Xiao Yao, Hua Jiang, Cuizhen Zhang, Huamao Wang, Lin Yang, Yongfeng Yu, Bizhi Shi, Zhiwei chen, Shujun Tian, Shun Lu, Zonghai Li （通讯作者）,Jianren Gu. Dikkopf-1 autoantibody is a novel serologic biomarker for non–small cell lung cancer (NSCLC). Biomarkers 2010 15(2):128-34
Lin Yang, Hua Jiang, Bizhi Shi, Huamao Wang, Jinjun Li, Hai Wang, Ming Yao, Zonghai Li （通讯作者） Identification and Characterization of Ch806 Mimotopes Cancer Immunology Immunotherapy 2010 59 (10): 1481-7
Huamao Wang&, Hua Jiang&, Min Zhou, Zhibing Xu, Shiguo Liu, Bizhi Shi, Xiao Yao, Ming Yao, JianRen Gu, Zonghai Li （通讯作者） Epidermal Growth Factor Receptor vIII enhances tumorigenicity and resistance to 5-Fluorouracil in Human Hepatocellular Carcinoma. Cancer letter 2009 279(1):30-8
Jiang Hua, Xiumei Cai, Bizhi Shi,Jie Zhang, Zonghai Li* （通讯作者）, Jianren Gu, Development of efficient RNA interference system using EGF-displaying phagemid particles Acta Pharmacol Sin. 2008 29(4):437-42.
Hua Jiang, Jie Zhang, Bizhi Shi, Yuhong Xu, Zonghai Li （通讯作者）, Jianren Gu, Application of EGFP-EGF Fusions to Explore the Mechanism of Endocytosis of Epidermal Growth Factor Receptor， Acta Pharmacol Sin 2007 28(1):111-7
Bizhi Shi, Huamao Wang, Shengrong Guo, Yuhong Xu, Zonghai Li （通讯作者）, Jianren Gu, Application of EGFP-EGF Fusions to Explore the Mechanism of Endocytosis of Epidermal Growth Factor Receptor， BioTechniques 2007 42（6）756-9
Liang Y, Shi B, Zhang J, Jiang H, Xu Y, Li Z （通讯作者）, Gu J. Better Gene Expression by (-)Gene than by (+)Gene in phage gene delivery systems. Biotechnology Progress 2006 22(3):626-30.
Zonghai Li （通讯作者）, Hua Jiang, Jie Zhang, Jianren Gu , Cell targeted phagemid particles preparation using E.coli bearing ligand-pIII encoding helper phage genome， BioTechniques 2006 41（6）：706-707.
Zonghai Li （共同第一作者）,Jie Zhang,Ruijiao Zhao,Yuhong Xu and Jianren Gu. Preparation of peptide-targeted phagemid particles using protein III modified helper phage. BioTechniques. 2005 39(4): 493-496.
Zonghai Li （共同第一作者）, Ruijiao Zhao, Xianghua Wu, Ye Sun, Ming Yao, Jinjun Li, Yuhong Xu, Jianren Gu. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 2005 19（14）：1978-1985